# Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin

Study · id `cardio:ct-nct05504226` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05504226](<https://clinicaltrials.gov/study/NCT05504226>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05504226

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 214 participants.

## Technical summary

Registry record NCT05504226. Randomized; quadruple masking; primary purpose treatment. Start 2022-10-12 (actual); primary completion 2023-11-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 214 participants (enrolled count; ClinicalTrials.gov record NCT05504226, source copy `cardio:ctgov-nct05504226-2025-01-27`, retrieved 2026-10-26)
- Started: 2022-10-12 (actual) (ClinicalTrials.gov record NCT05504226, source copy `cardio:ctgov-nct05504226-2025-01-27`, retrieved 2026-10-26)
- Primary completion: 2023-11-30 (actual) (ClinicalTrials.gov record NCT05504226, source copy `cardio:ctgov-nct05504226-2025-01-27`, retrieved 2026-10-26)
- Completion: 2024-06-18 (actual) (ClinicalTrials.gov record NCT05504226, source copy `cardio:ctgov-nct05504226-2025-01-27`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05504226, source copy `cardio:ctgov-nct05504226-2025-01-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05504226-2025-01-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin
- Acronym: TERA 305
- Condition: Type 2 Diabetes
- Intervention (Drug): Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
- Intervention (Drug): Teneligliptin Placebo Oral Tablet
- Lead sponsor: Handok Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Handok Inc. (`cardio:org-handok-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A 52-Week Efficacy and Safety Study of Teneligliptin, as an Add-On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial (TERA305 Study) (`cardio:pubmed-42832816`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 123689da1f086c2fc1e9e75496d5f15ff05b47d3b46edd763bf9eb5dc46eaa6f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
